Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment Strategies

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast CancerПодробнее

New and emerging agents in HER2-negative metastatic breast cancer: Implications for practiceПодробнее

New FDA-Approved Targeted Drug for Treatment-Resistant, ER Positive HER2 Negative Breast CancerПодробнее

Novel Strategies for HER2+ Metastatic Breast Cancer; BiosimilarsПодробнее

Updates in the Treatment of Metastatic Breast CancerПодробнее

Novel Approaches for HER2-Negative Metastatic Breast CancerПодробнее

Novel Therapeutics for Breast Cancer: HER2+ and Triple Negative Disease; New Pathways, TargetsПодробнее

Treatment and Issues For Triple Negative Breast Cancer-May 14, 2020Подробнее

Treatment strategies for HER2+ metastatic breast cancerПодробнее

TAK-228 Plus Hormonal Therapy for Metastatic, ER-Positive/HER2-Negative Breast CancerПодробнее

Expert Exchange: Clinical Implications of the Latest Advances in Metastatic Breast CancerПодробнее

Novel strategies for endocrine therapy: Can we do better?Подробнее

Improving the Management of Metastatic Breast Cancer: Novel and Emerging Treatments, Part IПодробнее

Exploring novel strategies for breast cancer treatmentПодробнее

Novel antibody-drug conjugates (ADCs) technologies for management of mBCПодробнее

WEBINAR: New Treatment Options for Metastatic Breast CancerПодробнее

First-Line Endocrine-Based Therapy for Patients with HR+, HER2-Negative Metastatic Breast CancerПодробнее

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Novel Combo Promising in Advanced HER2-Negative Breast Cancer - Medpage TodayПодробнее

Promising novel approaches to the treatment of TNBCПодробнее